Published on 22 August 2022
Description:
New PharmaTimes is out and a very modern edition it is too. It’s about the all-encompassing dominance of digital in industry and wider public health – it’s about agenda-setting medicine access being inseparable from digitalisation, patient centricity in the new world, how holistic medicine can combine with its digital counterpart and the vital role of AI in triggering health conversations.
Categories:
PharmaTimesPreview:
28 articles from this collection:
Cover
2 - Communique Awards
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - Covid-19
8 - Collaboration
9 - Prescribing
10-11 - COVER STORY: World in motion
12-13 - NHS: Guess who?
14-15 - DIGITAL HEALTHCARE: Generation game
16-17 - PUBLIC HEALTH: The good life?
18-19 - AI: Conversation starter
20 - PATIENTS: The difference a day makes
21 - SUSTAINABILITY: Biohazard
22-23 - GENOMES: Next gems
24-25 - DIGITAL NHS: Smart asks
26-27 - TALKING THERAPIES: Time trial
28 - NAKED EYE: Reality check
29 - PRECISION MEDICINE : Scotland, to be precise
30 - FLYPHARMA: FlyPharma Europe to land in Leipzig, Germany
31 - AI : We can see clearly now
32-33 - INDUSTRY: Cycle of life
34-35 - Your moves
36-37 - COVID-19: Triumph over adversity
38 - DIGITAL HEALTH: In the running
39 - PMPS
40 - PHARMATIMES
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.